Biogenera
Financials
Estimates*
EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|---|
EBITDA | <1m | (<1m) | (<1m) | (<1m) | (<1m) | (<1m) | (<1m) |
Profit | (<1m) | (<1m) | (<1m) | (<1m) | (<1m) | (<1m) | (<1m) |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
€1.5m | Seed | ||
N/A | Angel | ||
N/A | N/A | Seed | |
N/A | €187k | Seed | |
€2.9m Valuation: €70.0m -177.4x EV/LTM EBITDA | Seed | ||
* | €1.6m Valuation: €80.3m | Seed | |
Total Funding | AUD10.4m |
Related Content
Recent News about Biogenera
EditBiogenera operates in the biopharmaceutical sector, focusing on the research, development, and commercialization of innovative therapies for rare genetic diseases. The company serves patients, healthcare providers, and pharmaceutical partners by developing precision medicines that address unmet medical needs. Biogenera's business model revolves around leveraging advanced genetic research to create proprietary drugs, which are then brought to market through collaborations with larger pharmaceutical companies or direct commercialization. Revenue is generated through licensing agreements, partnerships, and direct sales of their therapeutic products. The company also engages in strategic alliances with universities, research centers, and certified incubators to enhance its research capabilities and accelerate drug development.
Keywords: biopharmaceuticals, genetic diseases, precision therapies, drug development, licensing, partnerships, healthcare, innovation, research, commercialization.